Wedbush Reiterates an 'Outperform' on Momenta (MNTA); Potential Upcoming Catalysts Include Copaxone Trial and Partnerships
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush reiterates an 'Outperform' on Momenta Pharmaceuticals (NASDAQ: MNTA), PT $27.
Wedbush analyst says, "Our fair value of $27 is calculated using a sum-of-parts analysis, applying a 30% annual discount to our peak annual sales estimate for M-Enoxaparin in DVT and ACS, M356 in Relapse-Remitting MS, and M118 in ACS, incorporating a 1-10 multiple for each based on stage of clinical risk. We use a probability weighted valuation for M-Enoxaparin, placing a 75% chance that another generic version will be approved in the future. Therefore, we believe significant upside to our fair value exists should M-Enox remain the sole generic on the market. In any event, however, we predict that M356 (generic Copaxone) will ultimately become MNTA’s most valuable drug. Given its best-in-class platform for copying the extraordinarily valuable field of complex therapeutics (including biologics), MNTA remains one of our favorite long-term picks."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $17.75 yesterday.
Wedbush analyst says, "Our fair value of $27 is calculated using a sum-of-parts analysis, applying a 30% annual discount to our peak annual sales estimate for M-Enoxaparin in DVT and ACS, M356 in Relapse-Remitting MS, and M118 in ACS, incorporating a 1-10 multiple for each based on stage of clinical risk. We use a probability weighted valuation for M-Enoxaparin, placing a 75% chance that another generic version will be approved in the future. Therefore, we believe significant upside to our fair value exists should M-Enox remain the sole generic on the market. In any event, however, we predict that M356 (generic Copaxone) will ultimately become MNTA’s most valuable drug. Given its best-in-class platform for copying the extraordinarily valuable field of complex therapeutics (including biologics), MNTA remains one of our favorite long-term picks."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $17.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
